Top

Published in:

01-03-2021 | Meningioma | Clinical Study

Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma

Authors: Edouard Samarut, Alexandre Lugat, Aymeric Amelot, Emeric Scharbarg, Samy Hadjadj, Claire Primot, Delphine Loussouarn, François Thillays, Kevin Buffenoir, Bertrand Cariou, Delphine Drui, Vincent Roualdes

Published in: Journal of Neuro-Oncology | Issue 1/2021

Abstract

Purpose

Meningiomas are the most common intracranial tumors, accounting for 20–30% of central nervous system tumors. Recently, the European Medicines Agency issued an alert on cyproterone acetate (CPA) based on the results of a study that found an increased risk of meningioma 7 to 20 times higher when a patient is on CPA.

The primary objective of this study was to determine the prevalence of CPA exposure in patients who had one or more intracranial meningiomas treated surgically or with radiation therapy. The secondary objectives were to establish a description of the patients who had intracranial meningioma in Nantes and to establish whether there was a difference in the intrinsic and tumoral characteristics of patients exposed to CPA compared with patients who had no hormonal exposure and patients who had been exposed to other hormones.

Methods

Monocentric, retrospective study including all patients treated by surgery or radiotherapy for intracranial meningioma from 2014 to 2017 excluding those with a history of exposure to ionizing radiation or neurofibromatosis type 2.

Results

388 patients were included, 277 were treated by surgery and 111 by radiotherapy. 3.9% of the patients had a history or current use of CPA, 16.2% were taking other hormonal treatment. Compared with the group without hormonal exposure, the CPA-exposed group had significantly an earlier onset of meningiomas at 48.9 vs. 61.9 years (p = 0.0005) and had more multiple meningiomas, 26.7% vs. 6.1% (p = 0.0115).

Conclusions

In our study, patients with a history or current use of CPA had significantly more meningiomas and were significantly younger at the onset.

Available only for authorised users

Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E et al (2008) Meningioma. Crit Rev Oncol Hematol 67:153–171. https://doi.org/10.1016/j.critrevonc.2008.01.010CrossRefPubMed

Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314. https://doi.org/10.1007/s11060-010-0386-3CrossRefPubMedPubMedCentral

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncol 17(Suppl 4):iv1-i62. https://doi.org/10.1093/neuonc/nov189CrossRefPubMedPubMedCentral

Cea-Soriano L, Wallander M-A, García Rodríguez LA (2012) Epidemiology of meningioma in the United Kingdom. Neuroepidemiology 39:27–34. https://doi.org/10.1159/000338081CrossRefPubMed

Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F et al (2018) Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie 64:15–21. https://doi.org/10.1016/j.neuchi.2014.11.013CrossRefPubMed

Yamanaka R, Hayano A, Kanayama T (2017) Radiation-induced meningiomas: an exhaustive review of the literature. World Neurosurg 97:635–644CrossRef

Yonehara S, Brenner AV, Kishikawa M, Inskip PD, Preston DL, Ron E et al (2004) Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995. Cancer 101:1644–1654. https://doi.org/10.1002/cncr.20543CrossRefPubMed

Kotecha RS, Pascoe EM, Rushing EJ, Rorke-Adams LB, Zwerdling T, Gao X et al (2011) Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol 12:1229–1239. https://doi.org/10.1016/S1470-2045(11)70275-3CrossRefPubMed

Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A et al (2018) Epidemiology of meningiomas. Neurochirurgie 64:5–14. https://doi.org/10.1016/j.neuchi.2014.05.006CrossRefPubMed

10.

Carroll RS, Glowacka D, Dashner K, Black PM (1993) Progesterone receptor expression in meningiomas. Cancer Res 53:1312–1316PubMed

11.

Neumann F (2009) The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol Diabetes 102:1–32. https://doi.org/10.1055/s-0029-1211261CrossRef

12.

Custer B, Longstreth W, Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152. https://doi.org/10.1186/1471-2407-6-152CrossRefPubMedPubMedCentral

13.

Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119:1152–1157. https://doi.org/10.1002/ijc.21950CrossRefPubMed

14.

Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM (2013) Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females: Clinical article. J Neurosurg 118:649–656. https://doi.org/10.3171/2012.9.JNS12811CrossRefPubMed

15.

Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen–progestin therapy. N Engl J Med 357:2411–2412. https://doi.org/10.1056/NEJMc071938CrossRefPubMed

16.

Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M et al (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien) 157:1741–1746. https://doi.org/10.1007/s00701-015-2532-3CrossRef

17.

Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968. https://doi.org/10.1111/j.1365-2125.2011.04031.xCrossRefPubMedPubMedCentral

18.

SIMPSON D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39. https://doi.org/10.1136/jnnp.20.1.22CrossRefPubMedPubMedCentral

19.

Cebula H, Pham TQ, Boyer P, Froelich S (2010) Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochir (Wien) 152:1955–1956. https://doi.org/10.1007/s00701-010-0787-2CrossRef

20.

ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (2016) Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia 48(10):1130–1137. https://doi.org/10.1111/and.12550CrossRefPubMed

21.

Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC (2018) Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 34:456–459. https://doi.org/10.4103/sni.sni_22_18CrossRef

22.

Bergoglio MT, Gómez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernández-Mijares A (2013) Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinol Nutr 60:264–267. https://doi.org/10.1016/j.endonu.2012.07.004CrossRefPubMed

23.

Anda T, Honda M, Ishihara T, Kamei T (2014) Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report. Neurol Med Chir (Tokyo) 54:327–330. https://doi.org/10.2176/nmc.cr2012-0417CrossRef

24.

Boetto J, Apra C, Bielle F, Peyre M, Kalamarides M (2018) Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene 37:4955–4963. https://doi.org/10.1038/s41388-018-0328-7CrossRefPubMed

25.

Passeri T, Champagne P-O, Bernat A-L, Hanakita S, Salle H, Mandonnet E et al (2019) Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir (Wien) 61:761–765. https://doi.org/10.1007/s00701-019-03848-xCrossRef

26.

Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C et al (2018) Progestin-associated shift of meningioma mutational landscape. Ann Oncol 29:681–686. https://doi.org/10.1093/annonc/mdx763CrossRefPubMed

27.

Peyre M, Salaud C, Clermont-Taranchon E, Niwa-Kawakita M, Goutagny S, Mawrin C et al (2015) PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget 6:32713–32722. https://doi.org/10.18632/oncotarget.5296CrossRefPubMedPubMedCentral

28.

Shimizu J, Matsumoto M, Yamazaki E, Yasue M (2008) Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 48:227–230. https://doi.org/10.2176/nmc.48.227CrossRef

29.

Kalamarides M, Peyre M (2017) Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment. World Neurosurg 101:814.e7-814.e10. https://doi.org/10.1016/j.wneu.2017.03.013CrossRef

30.

Islim AI, Mohan M, Moon RDC, Srikandarajah N, Mills SJ, Brodbelt AR et al (2019) Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol 142:211–221. https://doi.org/10.1007/s11060-019-03104-3CrossRefPubMedPubMedCentral

31.

Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG et al (2005) Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 114:797–805. https://doi.org/10.1002/ijc.20776CrossRefPubMed

32.

Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853. https://doi.org/10.3171/jns.2003.99.5.0848CrossRefPubMed

33.

Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164:629–636. https://doi.org/10.1093/aje/kwj254CrossRefPubMed

34.

Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol Off J Am Soc Clin Oncol 26:279–282. https://doi.org/10.1200/JCO.2007.14.2133CrossRef

35.

Shahin MN, Magill ST, Dalle Ore CL, Viner JA, Peters PN, Solomon DA et al (2019) Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. J Neurooncol 143:137–144. https://doi.org/10.1007/s11060-019-03147-6CrossRefPubMedPubMedCentral

36.

Roux A, Tauziede-Espariat A, Zanello M, Gareton A, Malaize H, Benzakoun J, Zah-Bi G, Oppenheim C, Plu-Bureau G, Chretien F, Pallud J (2020) Symptomatic progestin-associated atypical grade II meningioma. A first case report. Neurochirurgie 66:174–178. https://doi.org/10.1016/j.neuchi.2019.12.013CrossRefPubMed

37.

Apra C, Roblot P, Alkhayri A, Le Guérinel C, Polivka M, Chauvet D (2020) Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas. J Neurooncol 149:95–101. https://doi.org/10.1007/s11060-020-03576-8CrossRefPubMed

38.

Weill A, Cadier B, Nguyen P, Coste J (2019) Exposition à de fortes doses d’acétate de cyprotérone. Amélie Santé. https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/etudes-en-sante-publique/etudes-pharmaco-epidemiologiques/acetate-de-cyproterone-et-risque-de-meningiome.php

Title: Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma
Authors: Edouard Samarut
Alexandre Lugat
Aymeric Amelot
Emeric Scharbarg
Samy Hadjadj
Claire Primot
Delphine Loussouarn
François Thillays
Kevin Buffenoir
Bertrand Cariou
Delphine Drui
Vincent Roualdes
Publication date: 01-03-2021
Publisher: Springer US
Keywords: Meningioma
Hirsutism
Polycystic Ovary Syndrome
Meningioma
Radiotherapy
Polycystic Ovary Syndrome
Cyproterone Acetate
Published in: Journal of Neuro-Oncology / Issue 1/2021
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03683-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid

Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers

Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome

Aggresomes predict poor outcomes and implicate proteostasis in the pathogenesis of pediatric choroid plexus tumors

Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?

Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database